Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy
Blood · 2024
DOI: 10.1182/blood.2022019536 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Blood, 2024. Verfasst von Jonathan W Friedberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wilmot Cancer Institute, University of Rochester, Rochester, NY. Hauptthemen laut MEDLINE: Frailty, Hodgkin Disease, Immunoconjugates. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have inferior outcomes compared with younger patients, potentially due to comorbidities and frailty. This noncomparative phase 2 study enrolled patients aged ≥60 years with cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (part B) or nivolumab (part D; 3 mg/kg). In parts B and D, 50% and 38% of patients, respectively, had ≥3 general comorbidities or ≥1 significant comorbidity. Of the 22 patients treated with BV-DTIC, 95% achieved objective response, and 64% achieved complete response (CR). With a median follow-up of 63.6 months, median duration of response (mDOR) was 46.0 months. Median progression-free survival (mPFS) was 47.2 months; median overall survival (mOS) was not reached. Of 21 patients treated with BV-nivolumab, 86% achieved objective response, and 67% achieved CR. With 51.6 months of median follow-up, mDOR, mPFS, and mOS were not reached. Ten patients (45%) with BV-DTIC and 16 patients (76%) with BV-nivolumab experienced grade ≥3 treatment-emergent adverse events; sensory peripheral neuropathy (PN; 27%) and neutropenia (9%) were most common with BV-DTIC, and increased lipase (24%), motor PN (19%), and sensory PN (19%) were most common with BV-nivolumab. Despite high median age, inclusion of patients aged ≤88 years, and frailty, these results demonstrate safety and promising durable efficacy of BV-DTIC and BV-nivolumab combinations as frontline treatment, suggesting potential alternatives for older patients with cHL unfit for initial conventional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01716806.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wilmot Cancer Institute, University of Rochester, Rochester, NY.
- Georgia Cancer Specialists, Marietta, GA.
- Virginia Cancer Specialists, Fairfax, VA.
- Minnesota Oncology PA, Minneapolis, MN.
- Oncology and Hematology Associates of SW Virginia, Blacksburg, VA.
- Center for Cancer and Blood Disorders, Bethesda, MD.
ORCID-Profile: Jonathan W Friedberg, Christopher A Yasenchak
Zitieren
APA
Friedberg, J. W., Bordoni, R., Patel-Donnelly, D., Larson, T., Goldschmidt, J., Boccia, R., Cline, V. J. M., Mamidipalli, A., Liu, J., Akyol, A., & Yasenchak, C. A. (2024). Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. https://doi.org/10.1182/blood.2022019536
Vancouver
Friedberg JW, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024. doi:10.1182/blood.2022019536
BibTeX
@article{Friedberg2024,
author = {Friedberg, Jonathan W and Bordoni, Rodolfo and Patel-Donnelly, Dipti and Larson, Timothy and Goldschmidt, Jerome and Boccia, Ralph and Cline, Vivian J M and Mamidipalli, Adrija and Liu, Jingmin and Akyol, Alev and Yasenchak, Christopher A},
title = {Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy},
journal = {Blood},
year = {2024},
doi = {10.1182/blood.2022019536}
}
EUVIMED